We are thrilled to announce our investment in Genespire, a highly innovative Italian in-vivo gene therapy company addressing rare genetic diseases. The oversubscribed Series B financing round secured by a strong syndicate, which includes Sofinnova Partners, CDP Venture Capital SGR and Indaco Venture Partners, will bring the company all the way to clinical trials in a devastating pediatric indication. Special thanks to the Genespire team and to the former CEO, Julia Berretta, who played a key role in this successful achievement. ?? For more information, visit Genespire website following the link: https://lnkd.in/ggUw4S4q
Today we announced the closing of our €46.6M (~$52M) Series B #financing, co-led by Sofinnova Partners, XGEN Venture and CDP Venture Capital SGR through its Large Venture Fund forming a strong syndicate with Indaco Venture Partners. The financing will enable the development of GENE202, the Company’s lead candidate, up to a Phase I/II clinical trial for the treatment of MMA, a devastating genetic disorder impairing the metabolism of certain amino acids and fats. GENE202, developed by Genespire’s scientific co-founders and gene therapy leaders, Pr. Luigi Naldini and Dr. Alessio Cantore at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), is a pioneering in vivo off-the-shelf gene therapy which harnesses the company’s Immune Shielded Lentiviral Vector (ISLV) platform to address pediatric patients affected by genetic diseases who currently face the most pressing unmet medical needs, while also benefitting adult patients. ? ? Special thanks to our previous CEO, Julia Berretta who was instrumental in delivering this successful financing. To read the full press release visit: https://lnkd.in/eQ7Q2dnq #GeneTherapy #BiotechInnovation #LentiViralVectors #Pediatric #Biotech #Innovation #Methylmalonicacidemia #RareDiseases